<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813357</url>
  </required_header>
  <id_info>
    <org_study_id>AH-491/12</org_study_id>
    <secondary_id>ACTRN12612001082897</secondary_id>
    <nct_id>NCT01813357</nct_id>
  </id_info>
  <brief_title>Does Rosuvastatin Delay Progression of Atherosclerosis in HIV</brief_title>
  <official_title>Does Rosuvastatin Delay Progression of Atherosclerosis in People With HIV Infection at Moderate Cardiovascular Risk? A Multicentre Randomized, Double Blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomised double blind placebo controlled trial comparing Rosuvastatin with
      placbeo in HIV positive people who are at intermediate cardiovascular risk.

      It is possible that HIV positive people will receive a greater benefit from statins because
      of their higher baseline levels of inflammation. Current Australian guidelines recommend
      initiation of statin therapy on the basis of cholesterol level and the presence of other risk
      factors for heart disease (such as diabetes) but do not take into account whether a patient
      is infected with HIV. This study aims to determine what benefit HIV infected people will
      receive from starting statin therapy earlier then currently recommended.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomised to receive either the active agent (Rosuvastatin) or a
      placebo once daily for 96 weeks.

      Participants will undergo blood tests and ultrasounds of the arteries of the neck (carotid
      intima media thickness) prior to starting Rosuvastatin and then after 1 and 2 years on the
      drug to determine what effect it has on markers of inflammation, cholesterol levels and
      thickness of blood vessels.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of carotid intima media thickness</measure>
    <time_frame>Baseline, 1 and 2 years</time_frame>
    <description>Carotid intima media thickness will be measured by ultrasonography and the change from baseline at 1 and 2 years calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of adverse events</measure>
    <time_frame>Will be calculated every 12 weeks and formally reported at 1 and 2 years of followup</time_frame>
    <description>Number of participants with adverse events in total and also the number of participants with adverse events thought secondary to the study medication</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of rosuvastatin on immunological and inflammatory markers</measure>
    <time_frame>Baseline, 48 and 96</time_frame>
    <description>The following markers will be measured at baseline and week 48 and 96. Concentrations of each marker will be compared at the three time points.
hsCRP
d-dimer
Panel of markers of innate immune function including: CD14, CD16, CD38, CDD11b, CX3CR1, sCD163, IL6, sCD14 &amp; CCL2)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>HIV</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill that is encapsulated so as to appear identical to the active agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>encapsulated tablet 20mg daily</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Brand name: Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo arm included to maintain blinding</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Moderate cardiovascular disease (CVD) risk, (10-15% 10 year risk of CVD)

          -  HIV positive

          -  Stable combination anti-retroviral therapy (cART) with plasma HIV viral load
             &lt;200copies/ml for ≥ 6 months

        Exclusion Criteria:

          -  Recommended use of lipid lowering therapy according to Australian guidelines

          -  Prior use of statin, fibrate, ezetimibe within the last six months

          -  Contraindication to statin use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Hoy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alfred health, Monash University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Hoy</last_name>
    <email>jennifer.hoy@monash.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer Hoy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospitaux Universitaires de Geneve</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Calmy</last_name>
      <phone>+41 0223729812</phone>
    </contact>
    <investigator>
      <last_name>Alexandra Calmy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>July 12, 2014</last_update_submitted>
  <last_update_submitted_qc>July 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Statin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

